Zynerba Pharmaceuticals Inc
Zynerba Pharmaceuticals: Analysts See More Upside after the Rally
So far, Zynerba Pharmaceuticals (ZYNE) has seen an upwards price action of 265% in 2019. Analysts see more upside in the stock.
PE Ratio and the Basic Science of Stock Valuation
Ratio analysis is a commonly used method of stock valuation. Among the most popular ratios, most investors tend to look at PE.
Zynerba Pharmaceuticals Rises Due to Patent News
Zynerba Pharmaceuticals (ZYNE) has risen 18.6% as of 10:40 AM EST on June 11. The stock has year-to-date gains of more than 300%.